Cirrhotic patients with esophagogastric varices and non-acute upper gastrointestinal bleeding
Conditions
Interventions
Dezocine group (Group A):None
Pentazocine group (Group B):None
Propofol control group (Group C):None
Dakronine control group (Group D):None
Sponsors
the Third Central Hospital of Tianjin
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria of dezocine group (group A, n=100) and pentazocine group (group B, n=100) were consistent, according to the indications specified in the 2018 Technical Specifications for sedation/anesthesia in the diagnosis and treatment of digestive endoscopy: (1) Patients with cirrhosis of the esophagus and gastric varices and non-acute upper gastrointestinal bleeding confirmed by imaging and pathology required endoscopic diagnosis and treatment. (2) All patients who are willing to undergo mild or moderate sedation due to medical needs and have no contraindications with related drugs and gastroscopy. (3) Patients who have concerns or fear about the diagnosis and treatment of digestive endoscopy and are highly sensitive and cannot control themselves. (4) ASA Grade I and II patients with good general condition and ASA grade III and IV patients in stable state shall be implemented under close monitoring as appropriate. Propofol control group (group C, n=100) : (1) Patients with cirrhosis of the esophagus and gastric fundus varices and non-acute upper gastrointestinal bleeding were confirmed by imaging and pathology and required endoscopic treatment. (2) All patients who are willing to undergo anesthesia/deep sedation for digestive endoscopy and have no contraindications for propofol and gastroscopy due to medical needs. (3) Patients who have concerns or fear about the diagnosis and treatment of digestive endoscopy and are highly sensitive and cannot control themselves. (4) ASA Grade I and II patients with good general condition and ASA Grade III patients in stable state shall be implemented under close monitoring as appropriate. (5) operation for a long time, complex operation of endoscopic diagnosis and treatment technology, such as endoscopic mucosal resection (EMR) endoscopicmucosalresection, etc. Dachronine control group (group D, n=100) : (1) Patients with non-acute upper gastrointestinal bleeding from esophageal and fundus varices in cirrhosis of the liver confirmed by imaging and pathology required gastroscopy. (2) All patients who are not contraindicated by dachronine and gastroscopy due to medical needs and are willing to accept oral pharyngeal surface anesthesia for digestive endoscopy. (3) Patients who have no concerns or fear about the diagnosis and treatment of digestive endoscopy and can control themselves.
Exclusion criteria
Exclusion criteria: The exclusion criteria of dezocine group (group A, n=100), pentazocine group (group B, n=100) and propofol control group (group C, n=100) were consistent, and contraindications were prescribed according to the 2018 Technical specifications for sedation/anesthesia in the diagnosis and treatment of digestive endoscopy in China: (1) patients with contraindications for routine gastroscopy or refusal of sedation. (2) Patients with ASA grade ? and above. (3) People who have allergies to sedative/anesthetic drugs and other serious anesthesia risks. (4) Patients with liver dysfunction (Child-PughC grade or above), acute upper gastrointestinal bleeding, severe anemia, and gastrointestinal obstruction accompanied by retention of stomach contents. (5) Patients with potentially life-threatening circulatory and respiratory diseases that are not properly controlled, such as uncontrolled severe hypertension, severe arrhythmia, unstable angina, acute respiratory infections, asthma attacks, etc. (6) Identify patients with difficult airway, such as mouth opening disorder, limited movement of cervical frequency, rheumatoid spondylitis, arthritis of the face, etc. (7) Severe neurological diseases (such as stroke, hemiplegia, convulsion, epilepsy, etc.). (8) Patients with a history of drug abuse, too old or too young, morbid obesity, and difficulty in urination. Dakronin control group (D group, n=100) : (1) gastroscopy contraindications. (2) dcloninol allergy. (3) Items (4-8) of the exclusion criteria of groups A, B and C.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Respiratory depression during surgery;Hypotension;Bradycardia;Hypoxemia;Physical activity;Choking;Injection pain;Shiver;What happened during the operation;Visual analogue scale score of intraoperative analgesia;Ramsay calm score;Drug induction time;Recovery time after surgery;Waking time;ECG before anesthesia induction (T0), after induction (T1), at admission (T2), during surgery (T3), and at wakeup after surgery (T4);Systolic blood pressure before anesthesia induction (T0), after induction (T1), at admission (T2), during surgery (T3), and at wakeup after surgery (T4);Diastolic blood pressure before anesthesia induction (T0), after induction (T1), at admission (T2), during surgery (T3), and at wakeup after surgery (T4);Mean arterial pressure before anesthesia induction (T0), after induction (T1), at admission (T2), during surgery (T3), and at wakeup after surgery (T4);Heart rate before anesthesia induction (T0), after induction (T1), at admission (T2), during surgery (T3), and at wakeup after surgery (T4);Respiratory rate before anesthesia induction (T0), after induction (T1), at admission (T2), during surgery (T3), and at wakeup after surgery (T4);SpO2 before anesthesia induction (T0), after induction (T1), at admission (T2), during surgery (T3), and at wakeup after surgery (T4); | — |
Secondary
| Measure | Time frame |
|---|---|
| Operation time;Score of each operation; | — |
Countries
China
Contacts
Public ContactMinghui Zhu
the Third Central Hospital of Tianjin
Outcome results
None listed